Investigators revealed a significant association between vitamin D deficiency and increased risk of neuromyelitis optica spectrum disorder, highlighting the possible impact of vitamin D on NMOSD ...

Once frequently misdiagnosed as multiple sclerosis, NMOSD now has better diagnostic tests and better treatments to prevent relapses.

NMOSD and New Treatment Frontiers —In recent years, the U.S. Food and Drug Administration (FDA) has looked favorably on new therapies for neuromyelitis optica spectrum disorder (NMOSD). Here’s ...

Patients with rare NMOSD have treatment options Three therapies have been approved by the FDA to reduce relapses in patients.

Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti–aquaporin-4 (AQP4-IgG) in approximately two ...

NMOSD is a rare and debilitating autoimmune disease driven by severe, recurrent central nervous system (CNS) attacks which can result in blindness, paralysis, and death.

Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated ...

Neuromyelitis optica, or NMO, is also called neuromyelitis optica spectrum disorder (NMOSD) and Devic disease. It is a disease that affects your eyes and spinal cord. It's not very common -- only ...

Christine Ha, winner of the third season of MasterChef, partners with the NMOSD community to encourage others to share their unstoppable stories.